FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For period ending May 06, 2008
GlaxoSmithKline plc
(Name of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F
or Form 40-F
Form 20-F x Form 40-F
--
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes No x
--
Notification of Transactions of Directors, Persons Discharging
Managerial Responsibility or Connected Persons
The Administrators of the GlaxoSmithKline Performance Share Plan notified the
Company and the under-mentioned persons on 6 May 2008 of an increase in their
notional interests in Ordinary shares at a price of GBP11.20 per share and
Ordinary Share ADRs at a price of $44.11 per ADR following the notional
re-investment of the dividend to be paid to shareholders on 10 July 2008.
Ordinary shares ADRs
Dr JP Garnier 5,730.80
Mr A P Witty 4,604.87
Mr J S Heslop 3,742.11
Dr M M Slaoui 332.90 1,657.54
Mrs C E Bruck Slaoui 26.53 37.72
Mr C Viehbacher 1,508.67
Mr J M Clarke 2,790.11
Mr M Dunoyer 1,050.82
Mr E J Gray 870.97
Dr R G Greig 917.26
Mr D Learmouth 573.76
Mr W C Louv 666.68
Mr D J Phelan 1,412.58
Dr D Pulman 917.26
Mr S M Werner 191.52
The notional dividends accrued will be paid out in proportion to the percentage
of participants' Performance Share Plan holdings that vest following the end of
the relevant three year measurement period.
This notification relates to transactions notified in accordance with Disclosure
and Transparency Rules 3.1.4R(1)(a).
S M Bicknell
Company Secretary
6 May 2008
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorised.
GlaxoSmithKline plc
(Registrant)
Date: May 06, 2008 By: VICTORIA WHYTE
------------------
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc